Doctor of Podiatric Medicine Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Spencer Heninger

Podiatrist, Foot & Ankle Surgery Brigham City, UT Doctor of Podiatric Medicine

NPI 1790781292 CMS profile 898261

1030 S Medical Dr Ste A, Brigham City, UT 84302

Open in the dashboard

General payments

$3,480

28 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Spencer Heninger of Brigham City, UT is reported in the CMS Open Payments database as having received $3,480 across 28 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $84 3
2023 General $1,952 13
2022 General $126 5
2021 General $1,249 4
2020 General $40 2
2019 General $29 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Spencer Heninger
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Spencer Heninger were reported at $0. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Spencer Heninger Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $29 $389 $118–$1,406 $163
2020 $40 $191 $62–$691 $114
2021 $1,249 $329 $104–$1,341 $132
2022 $126 $419 $125–$1,611 $149
2023 $1,952 $377 $128–$1,164 $160
2024 $84 $394 $134–$1,168 $164
2025 $0 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Active Medical, LLC $2,964 7 payments
  2. Nevro Corp. $95 3 payments
  3. Nalu Medical, Inc. $57 3 payments
  4. Boston Scientific Corporation $56 2 payments
  5. Siemens Medical Solutions USA, Inc. $51 1 payment
  6. Pacira Pharmaceuticals Incorporated $48 1 payment
  7. Stryker Corporation $39 1 payment
  8. Orthofix Medical, Inc. $30 2 payments
  9. GRT US Holding, Inc. $30 2 payments
  10. Arthrex, Inc. $24 1 payment
  11. Other $87 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Travel and Lodging $1,559 3 payments
  2. Education $1,200 1 payment
  3. Food and Beverage $721 24 payments
Products named General payments · program years 2019–2024
  1. Senza $95 3 payments
  2. Physio-Stim $60 4 payments
  3. Nalu Neurostimulation System $57 3 payments
  4. MAGNETOM Free.Max $51 1 payment
  5. Iovera $48 1 payment
  6. Zilretta $48 1 payment
  7. INVISION $39 1 payment
  8. Qutenza $30 2 payments
  9. SPECTRA WAVEWRITER $29 1 payment
  10. GENERAL - PAIN MANAGEMENT $27 1 payment
  11. Other $100 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

157

Median for Podiatry: 160

Drug cost

$2,659

Median for Podiatry: $2,368

Branded share of claims

24.2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 32 $713
Cephalexin Generic 37 $710
Ibuprofen Generic 23 $415
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 38 $374
Celecoxib Generic 14 $332
Mupirocin Generic 13 $115

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$52,346

Of which drugs: $119

Medicare patients

194

Average age 75

Services billed

1,035

117 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 56%
Diabetes 39%
Depression 27%
Chronic kidney disease 26%
Ischemic heart disease 24%
Heart failure 19%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 36 138 $101
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 35 156 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

28 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record